FDA Offers Speedier Approvals to Drug Companies Aligning With 'National Priorities'
By Stephanie Brown HealthDay Reporter
WEDNESDAY, June 18, 2025 -- On Tuesday, the U.S. Food and Drug Administration announced a new initiative to offer expedited reviews for new medicines, an initiative that will apply to drugs that administration officials determine promote "the health interests of Americans."
The initiative, referred to as the Commissioner's National Priority Voucher program, allows drug developers to participate in a novel FDA priority program. The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10 to 12 months to one to two months.
This new process convenes experts from various FDA offices for a team-based review, which differs from the standard review system in which a drug application is sent to numerous FDA offices. Clinical information will be reviewed by a multidisciplinary team of physicians and scientists. This team will prereview all submitted information and then convene for a one-day "tumor board-style" meeting.
"Using a common-sense approach, the national priority review program will allow companies to submit the lion's share of the drug application before a clinical trial is complete so that we can reduce inefficiencies. The ultimate goal is to bring more cures and meaningful treatments to the American public," FDA Commissioner Marty Makary, M.D., M.P.H., said in a statement. "As a surgical oncologist, we often made multidisciplinary decisions with a team of doctors on major life-and-death questions for patients, incorporating the latest medical studies in a one-day tumor board-style discussion. This voucher harnesses that model to deliver timely decisions for drug developers."
Specific criteria will be used to make the vouchers available to companies aligned with what the FDA considers national health priorities: confronting health crises in the United States; providing more innovative cures for the American people; fulfilling unmet public health needs; and expanding domestic drug manufacturing as a national security issue.
Qualifying drug manufacturers must submit the chemistry, manufacturing, and controls section of their application and the draft labeling at least 60 days prior to submitting their final application. They will also be expected to keep in communication and provide prompt responses to FDA inquiries during the review process.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Waist-to-Height Ratio Predicts Liver Steatosis and Fibrosis
WEDNESDAY, June 18, 2025 -- Waist-to-height ratio (WHtR) outperforms body mass index (BMI) in detecting the risk for liver disease, according to a study published in the July...
Virtual Reality Training Module May Aid Infection Control Efforts
TUESDAY, June 17, 2025 -- Users report positive experiences and engagement with a virtual reality tool that trains clinicians on core concepts in infection control, including...
2,770 Cases of Arboviral Disease Reported in 48 States and D.C. in 2023
TUESDAY, June 17, 2025 -- In 2023, 48 states and the District of Columbia reported 2,770 human arboviral disease cases, with West Nile Virus (WNV) being the most common, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.